Skip to main content
Erschienen in: Journal of Neurology 4/2015

01.04.2015 | Letter to the Editors

Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS

verfasst von: F. Lauda, T. Fangerau, K. Javaheripour-Otto, E. Pinkhardt, J. Kassubek, H. Tumani

Erschienen in: Journal of Neurology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sirs, …
Literatur
1.
Zurück zum Zitat Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ et al (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80(15):1430–1438PubMedCentralCrossRefPubMed Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ et al (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80(15):1430–1438PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438–446CrossRefPubMed Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438–446CrossRefPubMed
3.
Zurück zum Zitat Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C et al (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84(10):1068–1074PubMedCentralCrossRefPubMed Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C et al (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84(10):1068–1074PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T et al (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361(11):1081–1087CrossRefPubMed Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T et al (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361(11):1081–1087CrossRefPubMed
5.
Zurück zum Zitat Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B et al (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72(5):402–409PubMedCentralCrossRefPubMed Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B et al (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72(5):402–409PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Tan IL, McArthur JC, Clifford DB, Major EO, Nath A (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77(11):1061–1067PubMedCentralCrossRefPubMed Tan IL, McArthur JC, Clifford DB, Major EO, Nath A (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77(11):1061–1067PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Thaker AA, Schmitt SE, Pollard JR, Dubroff JG (2014) Natalizumab-induced progressive multifocal leukoencephalopathy. Clin Nucl Med 39(7):e365–e366CrossRefPubMed Thaker AA, Schmitt SE, Pollard JR, Dubroff JG (2014) Natalizumab-induced progressive multifocal leukoencephalopathy. Clin Nucl Med 39(7):e365–e366CrossRefPubMed
8.
Zurück zum Zitat Kuhle J, Gosert R, Buhler R, Derfuss T, Sutter R, Yaldizli O et al (2011) Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 77(23):2010–2016PubMedCentralCrossRefPubMed Kuhle J, Gosert R, Buhler R, Derfuss T, Sutter R, Yaldizli O et al (2011) Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 77(23):2010–2016PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Calic Z, Cappelen-Smith C, Hodgkinson SJ, McDougall A, Cuganesan R, Brew BJ (2014) Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. J Clin Neurosci. doi:10.1016/j.jocn.2014.08.016 Calic Z, Cappelen-Smith C, Hodgkinson SJ, McDougall A, Cuganesan R, Brew BJ (2014) Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. J Clin Neurosci. doi:10.​1016/​j.​jocn.​2014.​08.​016
10.
Zurück zum Zitat Stuve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A et al (2007) Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 64(2):169–176CrossRefPubMed Stuve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A et al (2007) Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 64(2):169–176CrossRefPubMed
11.
Zurück zum Zitat Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O et al (2014) Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2014-307582 PubMed Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O et al (2014) Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. doi:10.​1136/​jnnp-2014-307582 PubMed
12.
Zurück zum Zitat Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A et al (2013) Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler 19(9):1209–1212CrossRefPubMed Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A et al (2013) Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler 19(9):1209–1212CrossRefPubMed
Metadaten
Titel
Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS
verfasst von
F. Lauda
T. Fangerau
K. Javaheripour-Otto
E. Pinkhardt
J. Kassubek
H. Tumani
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 4/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7658-y

Weitere Artikel der Ausgabe 4/2015

Journal of Neurology 4/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.